Centessa Pharmaceuticals (CNTA) Assets Average (2021 - 2026)

Centessa Pharmaceuticals (CNTA) has 6 years of Assets Average data on file, last reported at $664.6 million in Q1 2026.

• Quarterly Assets Average rose 20.33% year-over-year to $664.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $664.6 million (up 20.33% YoY) and the FY2025 annual result came in at $632.1 million, up 34.92% from the prior year.
• Assets Average climbed to $664.6 million in Q1 2026 per CNTA's latest filing, from $567.9 million in the prior quarter.
• Across five years, Assets Average topped out at $664.6 million in Q1 2026 and bottomed at $344.2 million in Q1 2024.
• The 5-year median for Assets Average is $500.2 million (2022), against an average of $486.3 million.
• The widest annual swing landed in 2023, when Assets Average slumped 30.01%; it then jumped 60.86% in 2024.
• Tracing CNTA's Assets Average over 5 years: stood at $461.8 million in 2022, then fell by 20.14% to $368.8 million in 2023, then jumped by 60.86% to $593.3 million in 2024, then retreated by 4.27% to $567.9 million in 2025, then climbed by 17.03% to $664.6 million in 2026.
• Per Business Quant, the three latest CNTA Assets Average figures stand at $664.6 million (Q1 2026), $567.9 million (Q4 2025), and $470.2 million (Q3 2025).

Peer Comparison